

## ***i*SCREEN ACCURACY DATA**

### **AMPHETAMINE (AMP) DRUG SCREEN**

**Accuracy:** The performance of the the *i*SCREEN amphetamine drug screen was compared to the laboratory initial screen and a leading commercially available amphetamine rapid test. Testing was performed on 300 clinical specimens. **At least ten percent of the specimens evaluated were between -25% or +25% of the cut-off concentration of 1,000 ng/ml.** Presumptive positive results were confirmed by GC/MS.

When compared to GC/MS at 500 ng/mL, the results are provided in the table below:

Method		GC/MS		Total Results
Results		Positive	Negative	
<i>i</i> SCREEN Test Device	Positive	142	0	142
	Negative	9	149	158
<b>Total Results</b>		151	149	300

Relative Sensitivity: 94% Relative Specificity: >99% Accuracy: 97%

**Note:** The FDA requires on-site test devices to be accurate within +25% of the drug screen's cut-off level. The *i*SCREEN detected 100% of the GC/MS positive specimens within 25% of the screen's 1000ng cut-off.

The only GC/MS positive specimens not identified as positive by the *i*SCREEN were close to or below the *i*SCREEN 's 1000 ng/ml cut-off. Specimens whose results differed between GC/MS and the *i*SCREEN contained the following concentration levels in ng/ml:

(781,862, 878, 898, 898, 1000, 1032, 1137, and 1204).

### **METHAMPHETAMINE (mAMP) DRUG SCREEN**

**Accuracy:** The performance of the the *i*SCREEN methamphetamine drug screen was compared to the laboratory initial screen and a leading commercially available amphetamine rapid test. Testing was performed on 300 clinical specimens. **At least ten percent of the specimens evaluated were between -25% or +25% of the cut-off concentration of 1,000 ng/ml.** Presumptive positive results were confirmed by GC/MS.

When compared to GC/MS at 500 ng/mL, the results are provided in the table below:

Method		GC/MS		Total Results
Results		Positive	Negative	
<i>i</i> SCREEN Test Device	Positive	145	0	145
	Negative	1	154	155
<b>Total Results</b>		146	154	300

Relative Sensitivity: >99% Relative Specificity: >99% Accuracy: >99%

**Note:** The *i*SCREEN detected 100% of the GC/MS positive specimens at or above the screen's 1000ng cut-off.

The only GC/MS positive specimen not identified as positive by the *i*SCREEN was below the *i*SCREEN 's 1000 ng/ml cut-off. The discrepant specimen contained d-methamphetamine at a concentration of 954 ng/ml.

### **MARIJUANA (THC) DRUG SCREEN**

**Accuracy:** The performance of the the *i*SCREEN amphetamine drug screen was compared to the laboratory initial screen and a leading commercially available marijuana rapid test. Testing was performed on 300 clinical specimens. **At least ten percent of the specimens evaluated were between -25% or +25% of the cut-off concentration of 50 ng/ml.** Presumptive positive results were confirmed by GC/MS.

When compared to GC/MS at 15 ng/mL, the results are provided in the table below:

Method		GC/MS		Total Results
Results		Positive	Negative	
<i>i</i> SCREEN Test Device	Positive	143	0	143
	Negative	7	150	157
<b>Total Results</b>		150	150	300

Relative Sensitivity: 95% Relative Specificity: >99% Accuracy: 98%

**Note:** The FDA requires on-site test devices to be accurate within 25% of the drug screen's cut-off level. The *i*SCREEN detected all but two of the GC/MS positive specimens within +25% of the screen's 50ng cut-off.

The only GC/MS positive specimens not identified as positive by the *i*SCREEN were close to or below the *i*SCREEN 's 50 ng/ml cut-off. Specimens whose results differed between the GC/MS and the *i*SCREEN contained the following concentration levels in ng/ml: (15, 15, 16, 32, 51, 73, and 79)

# iSCREEN ACCURACY DATA

## COCAINE DRUG SCREEN

**Accuracy:** The performance of the the *iSCREEN* cocaine drug screen was compared to the laboratory initial screen and a leading commercially available amphetamine rapid test. Testing was performed on 300 clinical specimens. **At least ten percent of the specimens evaluated were between -25% or +25% of the cut-off concentration of 300 ng/ml.** Presumptive positive results were confirmed by GC/MS.

When compared to GC/MS at 150 ng/mL, the results are provided in the table below:

Method		GC/MS		Total Results
Results		Positive	Negative	
<i>iSCREEN</i> Test Device	Positive	136	0	136
	Negative	13	151	164
<b>Total Results</b>		149	151	300

Relative Sensitivity: 91% Relative Specificity: >99% Accuracy: 96%

**Note:** The FDA requires on-site test devices to be accurate within 25% of the drug screen's cut-off level. The *iSCREEN* detected all but one of the GC/MS positive specimens within 25% of the screen's 300ng cut-off.

The only GC/MS positive specimens not identified as positive by the *iSCREEN* were close to or below the *iSCREEN* 's 300 ng/ml cut-off. Specimens whose results differed between GC/MS and the *iSCREEN* contained the following concentration levels in ng/ml: (153, 158, 188, 202, 228, 233, 243, 254, 265, 270, 298, 358 and 381)

## OPIATES-2000 (OPI) DRUG SCREEN

**Accuracy:** The performance of the the *iSCREEN* opiates drug screen was compared to the laboratory initial screen and a leading commercially available opiates rapid test. Testing was performed on 300 clinical specimens. **At least ten percent of the specimens evaluated were between -25% or +25% of the cut-off concentration of 2,000 ng/ml.** Presumptive positive results were confirmed by GC/MS.

When compared to GC/MS at 2000 ng/mL, the results are provided in the table below:

Method		GC/MS		Total Results
Results		Positive	Negative	
<i>iSCREEN</i> Test Device	Positive	134	16	150
	Negative	0	150	150
<b>Total Results</b>		134	166	300

Relative Sensitivity: >99% Relative Specificity: 90% Accuracy: 95%

**Note:** The *iSCREEN* correctly identified 100% of the specimens determined to be positive by GC/MS.

The specimens identified as positive by the *iSCREEN* but below 2000 ng/ml by GC/MS were all at or above 1500 ng/ml. Therefore the *iSCREEN* performed at >99% accuracy within +/- 25% of the screens 2000 ng/ml cut-off.

## PCP DRUG SCREEN

**Accuracy:** The performance of the the *iSCREEN* PCP drug screen was compared to the laboratory initial screen and a leading commercially available PCP rapid test. Testing was performed on 212 clinical specimens. **At least ten percent of the specimens evaluated were between -25% or +25% of the cut-off concentration of 25 ng/ml.** Presumptive positive results were confirmed by GC/MS.

When compared to GC/MS at 25 ng/mL, the results are provided in the table below:

Method		GC/MS		Total Results
Results		Positive	Negative	
<i>iSCREEN</i> Test Device	Positive	50	5	55
	Negative	0	157	157
<b>Total Results</b>		50	162	212

Relative Sensitivity: 100% Relative Specificity: 97% Accuracy: 98%

**Note:** The *iSCREEN* correctly identified 100% of the specimens determined to be positive by GC/MS.

The specimens identified as positive by the *iSCREEN* but below 25 ng/ml by GC/MS were all at or above 15 ng/ml. Therefore; the *iSCREEN* detected 5 positive specimens that were below the 25 ng/ml GC/MS cut-off, but there were no false-positive results.

# *i*SCREEN ACCURACY DATA

## **BARBITURATES (BAR) DRUG SCREEN**

**Accuracy:** The performance of the the *i*SCREEN barbiturates drug screen was compared to the laboratory initial screen and a leading commercially available barbiturates rapid test. Testing was performed on 292 clinical specimens. **At least ten percent of the specimens evaluated were between -25% or +25% of the cut-off concentration of 300 ng/ml.** Presumptive positive results were confirmed by GC/MS.

When compared to GC/MS at 300 ng/mL, the results are provided in the table below:

Method		GC/MS		Total Results
Results		Positive	Negative	
<i>i</i> SCREEN Test Device	Positive	122	4	126
	Negative	10	156	166
Total Results		132	160	292

Relative Sensitivity: 92% Relative Specificity: 98% Accuracy: 95%

**Note:** The FDA requires on-site test devices to be accurate within 25% of the drug screen's cut-off level. The *i*SCREEN's accuracy within 25% of the screen's 300ng cut-off was 97%

The specimens identified as positive by the *i*SCREEN but below 300 ng/ml by GC/MS were all at or above 218 ng/ml. Therefore; the *i*SCREEN detected 4 positive specimens that were below the 300 ng/ml GC/MS cut-off, but there were no false-positive results.

## **BENZODIAZEPINE (BZO) DRUG SCREEN**

**Accuracy:** The performance of the the *i*SCREEN benzodiazepines drug screen was compared to the laboratory initial screen and a leading commercially available benzodiazepines rapid test. Testing was performed on 300 clinical specimens. **At least ten percent of the specimens evaluated were between -25% or +25% of the cut-off concentration of 300 ng/ml.** Presumptive positive results were confirmed by GC/MS.

When compared to GC/MS at 300 ng/mL, the results are provided in the table below:

Method		GC/MS		Total Results
Results		Positive	Negative	
<i>i</i> SCREEN Test Device	Positive	129	7	136
	Negative	5	159	164
Total Results		134	166	300

Relative Sensitivity: 96% Relative Specificity: 96% Accuracy: 96%

**Note:** The FDA requires on-site test devices to be accurate within 25% of the drug screen's cut-off level. The *i*SCREEN detected all but one of the GC/MS positive specimens within +25% of the screen's 300ng cut-off.

The only GC/MS positive specimens not identified as positive by the *i*SCREEN were close to or below the *i*SCREEN 's 300 ng/ml cut-off. Specimens whose results differed between the GC/MS and the *i*SCREEN contained the following concentration levels in ng/ml: (323,326, 334, 335, and 540)

The *i*SCREEN detected 5 positive specimens that were below the 300 ng/ml GC/MS cut-off, but there were no false-positive results.

## **METHADONE (MTD) DRUG SCREEN**

**Accuracy:** The performance of the the *i*SCREEN methadone drug screen was compared to the laboratory initial screen and a leading commercially available methadone rapid test. Testing was performed on 300 clinical specimens. **At least ten percent of the specimens evaluated were between -25% or +25% of the cut-off concentration of 300 ng/ml.** Presumptive positive results were confirmed by GC/MS.

When compared to GC/MS at 200 ng/mL, the results are provided in the table below:

Method		GC/MS		Total Results
Results		Positive	Negative	
<i>i</i> SCREEN Test Device	Positive	132	0	132
	Negative	1	167	168
Total Results		133	167	300

Relative Sensitivity: >99% Relative Specificity: >99% Accuracy: >99%

**Note:** The *i*SCREEN detected >99% of the GC/MS positive specimens at +/- 25% of the screens 300 ng/ml cut-off.

The only GC/MS positive specimen not identified as positive by the *i*SCREEN contained methadone at a concentration of 534 ng/ml.

The *i*SCREEN did not detect any specimens as positive that did not confirm by GC/MS at 200 ng/ml.

# ***i*SCREEN ACCURACY DATA**

## **TRICYCLIC ANTIDEPRESSANT (TCA) DRUG SCREEN**

**Accuracy:** The performance of the the *i*SCREEN TCA drug screen was compared to the laboratory initial screen and a leading commercially available TCA rapid test. Testing was performed on 200 clinical specimens. **At least ten percent of the specimens evaluated were between -25% or +25% of the cut-off concentration of 1,000 ng/ml.** Presumptive positive results were confirmed by HPLC.

When compared to HPLC at 300 ng/mL, the results are provided in the table below:

Method		HPLC		Total Results
Results		Positive	Negative	
<i>i</i> SCREEN Test Device	Positive	60	0	60
	Negative	0	140	140
Total Results		60	140	200

**Note:** The *i*SCREEN correctly identified 100% of the specimens determined to be positive by GC/MS, and all specimens identified as positive by the *i*SCREEN were confirmed positive by HPLC at or above a 300 ng/ml concentration level.  
There is no DHHS specified confirmation level for TCA

Relative Sensitivity: >99% Relative Specificity: >99% Accuracy: >99%



## Brought to You by Employee Drug Testing Ace

Buying discounted, accurate, high quality employment drug testing kits and services is affordable, fast, easy, safe and secure with **Employee Drug Testing Ace**. You can buy employment, pre-employment and employee drug and alcohol testing kits, services and supplies tailored for employers, TPAs, nursing homes, hospitals, manufacturing, moving companies, Department of Transportation DOT, local and Federal Government agencies, auto dealerships, construction, DOD, the work place, employment agencies and more.

Our easy to use [employee drug testing](#) kits are DOT Approved, CLIA Waived, FDA 510k Cleared and SAMHSA Compliant. We provide both onsite employment drug screening and offsite employee drug screening services along with SAMHSA certified confirmation and medical review officer (MRO) services. All [employment drug screening](#) kits are on sale, discounted, and have [bulk / volume discounts](#).

- **Pay No Taxes in the USA.**, except California.
- **100% Free UPS Standard Shipping** in the Continental U.S.A. for *All* Products.
- **100% Free FedEx Overnight Shipping** in the Continental U.S.A. for *All* Specimens sent in as part of our SAMHSA Certified Confirmation Drug Testing Service.
- Onsite Third Party Administered (TPA) Employee Drug and Alcohol Collection Services.
- Over 12,000 Offsite Employee Drug and Alcohol Testing Locations Nationwide.
- The most complete [Employment Drug Testing Resource Center](#) including: information, official documents, work place drug testing information, forms, work accident info, charts, videos, post accident drug testing info, training materials, contact lists, definitions and more!

We sell affordable and guaranteed [employee drug screening](#) kits and services available at the best prices. Our prices may be cheap but our drug testing kits are of the highest quality and accuracy. If you are in the market for discounted high quality pre-employment, employee, or [employment drug testing](#) and screening kits and services, visit us today. You will be happy you did!